Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by FredTheVoiceon Apr 15, 2021 7:23am
169 Views
Post# 32998977

RE:RE:RE:The reason no analysts took Thera seriously

RE:RE:RE:The reason no analysts took Thera seriously Lots of respect for all of you on this board, even with those I dont share the same opinion,

But the point here, as An-Alias said yesterday, as nothing to do with Montreal-Canada-Boston-U.S.

But, and I said that here before the earning call: IF they dont give a clear guidance that NASH is on track than the market will be fragile to give TH\THERF a "go to the next step stock wise". So, the next target, lets say: 8$US share price.....

It will come, but it takes a time after the PROCEED LETTER that is giving the shorts the momemtum, not the longs.

It will come.

And than, another "we have turned the corner, and the second curve" will occur.

May ? June ?.....its just there.....

And lets keep the eyes on the real objective: DECEMBER 2021.......if good result in oncology, we will all be in favor and position to cash a nice family vacation because we were patient enough to believe in those words from the new CEO: "Theratechnologies is at a unique point in its evolution, and we have a tremendous opportunity ahead of us,” said Paul Levesque, President and Chief Executive Officer at Theratechnologies. “We are particularly pleased with the swift advancement of our Phase 1 oncology program, which has dosed its first patient, and the continued progress we have made toward advancing our Phase 3 trial in NASH  "

FTV.
<< Previous
Bullboard Posts
Next >>